DWA
MIRM icon

Dorsey Wright & Associates’s Mirum Pharmaceuticals MIRM Stock Holding History

Dorsey Wright & Associates’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-412
Closed -$8K – 357
2020
Q3 		$8K Sell
412
-138
-25% -$2.96K ﹤0.01% 242
2020
Q2 		$11K Buy
+550
New +$9.19K ﹤0.01% 225

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Dorsey Wright & Associates's MIRM Position: Q4 2020 in Review

Dorsey Wright & Associates sold out of Mirum Pharmaceuticals (MIRM) in Q4 2020, closing a stake of 412 shares — an estimated $8K sold.

Dorsey Wright & Associates first reported a position in MIRM in Q2 2020 and held it in 2 quarters. The position peaked at $11K in Q2 2020. 72 funds tracked by Wall St. Rank hold MIRM as of Q4 2020.

  • Dorsey Wright & Associates reported no remaining Mirum Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 412 Mirum Pharmaceuticals shares in Q4 2020, an estimated $8K.
  • Dorsey Wright & Associates first reported a position in Mirum Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Dorsey Wright & Associates's Mirum Pharmaceuticals position peaked at $11K in Q2 2020.
  • 72 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2020.

Based on Dorsey Wright & Associates's 13F filing for Q4 2020, filed 28 Jan 2021.